Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Depreciation (2019 - 2025)

Historic Accumulated Depreciation for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $20.1 million.

  • 4D Molecular Therapeutics' Accumulated Depreciation rose 2952.23% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 2952.23%. This contributed to the annual value of $16.6 million for FY2024, which is 3899.6% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Accumulated Depreciation of $20.1 million as of Q3 2025, which was up 2952.23% from $18.8 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Accumulated Depreciation registered a high of $20.1 million during Q3 2025, and its lowest value of $4.2 million during Q1 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Accumulated Depreciation averaged around $10.7 million, with its median value being $9.8 million (2023).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Accumulated Depreciation skyrocketed by 6131.96% in 2023 and then skyrocketed by 2952.23% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Accumulated Depreciation stood at $5.3 million in 2021, then soared by 45.13% to $7.7 million in 2022, then skyrocketed by 54.4% to $11.9 million in 2023, then soared by 39.0% to $16.6 million in 2024, then grew by 20.97% to $20.1 million in 2025.
  • Its last three reported values are $20.1 million in Q3 2025, $18.8 million for Q2 2025, and $17.6 million during Q1 2025.